Leukodystrophies – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Leukodystrophies – Drugs In Development, 2024 report and make more profitable business decisions.
Leukodystrophies, a collection of rare genetic disorders impacting the central nervous system (CNS), specifically the brain and spinal cord, cause damage to the CNS’s white matter. This damage hampers or obstructs signals between nerve cells, resulting in varied symptoms such as movement difficulties, vision and hearing impairment, and cognitive challenges. Due to the multitude of leukodystrophy types with differing symptoms, diagnosis poses a challenge. Healthcare providers employ physical and neurological exams, medical history inquiries, imaging tests like MRI or CT scans, genetic testing, and lab tests to diagnose. While no cure exists, treatment concentrates on symptom relief and support, encompassing medications, therapies, and nutritional and educational interventions.
The Leukodystrophies drugs in development market research report provide comprehensive information on the therapeutics under development for Leukodystrophies, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Leukodystrophies and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Leukodystrophies | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 24 molecules, with 19 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Leukodystrophies therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Leukodystrophies pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Leukodystrophies treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Affinia TherapeuticsAmsterdam UMC
location VUmc
ArmaGen Inc
Carlos Health Institute III
Contera Pharma ApS
Denali Therapeutics Inc
Duke University
Gain Therapeutics Inc
Homology Medicines Inc
Ionis Pharmaceuticals Inc
Myrtelle Inc
Neuway Pharma GmbH
Oligogen Inc
Orchard Therapeutics Plc
Recursion Pharmaceuticals Inc
Sana Biotechnology Inc
Shenzhen Geno-Immune Medical Institute
Shenzhen Hemogen Gene Biotechnology Co Ltd
Shenzhen Second People's Hospital
SynaptixBio Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Leukodystrophies reports